Bulletin du cancer最新文献

{"title":"[Peginterferon alfa-2a monotherapy in essential thrombocythemia].","authors":"Yaquine Mechelfekh, Gaspar Aspas Requena","doi":"10.1016/j.bulcan.2024.11.012","DOIUrl":"10.1016/j.bulcan.2024.11.012","url":null,"abstract":"","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"115-116"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Sexual health in cancer care: A cross-section of patients and professionals from a patient association].","authors":"Agnès Douvrel, Xavier Fenouil, Stéphanie Testu, Eva Guillot, Guillaume Buiret, Claire Combe","doi":"10.1016/j.bulcan.2024.11.007","DOIUrl":"10.1016/j.bulcan.2024.11.007","url":null,"abstract":"<p><p>Sexual health is a central aspect of the well-being and quality of life of cancer patients. Through two separate surveys, one conducted among patients and the other among professionals, we assessed the needs and practices relating to sexual health in cancer care. The results showed that the importance attached to taking intimate and sexual life into account was fairly high, but that 44% of patients had discussed the subject with a professional, and the majority had done so on their own initiative. The types of support requested were a dedicated consultation (38%) and exchanges with other people with cancer (21%). More than half of the professionals did not discuss sexual health with their patients. The needs identified were specific training, time to exchange and share experiences with other professionals, and resources (documentation, reference websites). Professional training and appropriate tools seem necessary to meet patients' expectations.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"199-207"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing the management of immune-related adverse events and survival in patients with thoracic cancer receiving immunotherapy through artificial intelligence (electronic patient-reported outcomes): The IMPATHI study.","authors":"Serge Amouin, Laurent Brureau, Charles Parnot, Hugo Picchi, Audrey Le Roy, Aline Barhli, Marie-Anne Audisio, Marie Pautas, Juliette Brezun, Antoine Schernberg, Hélène Vanquaethem, Carole Helissey","doi":"10.1016/j.bulcan.2024.11.004","DOIUrl":"10.1016/j.bulcan.2024.11.004","url":null,"abstract":"<p><strong>Introduction: </strong>The lung cancer continues to be the primary cause of cancer-related deaths, despite significant advancements in treatment through the introduction of immunological checkpoint inhibitors (ICI). These inhibitors, initially used as monotherapy, are now employed in combined therapies, resulting in improved survival rates. The ICI function by restoring T-cell activity to target tumor cells, but may lead to undesirable immune-related adverse events (irAE), necessitating careful management.</p><p><strong>Methods: </strong>The IMPATHI study, a prospective observational study conducted at the Begin Military Hospital, evaluated patient adherence to ePRO-based telemonitoring using the Cureety platform. The study included patients with advanced thoracic cancer receiving immunotherapy. Minors and those who did not consent to digital surveillance were excluded. Patients filled out ePRO questionnaires, and their health status was classified into four levels. The primary objective was compliance evaluation, with secondary objectives including tolerance profile and impact on survival.</p><p><strong>Results: </strong>The study recruited 22 patients, with a median age of 66years. Adenocarcinoma was the most common diagnosis, and 91% of patients had metastatic disease. Patient adherence to the telemonitoring platform was 83.3%, with 64% of responses indicating stable conditions. Common adverse events included asthenia, dyspnea, and joint/muscle pain. The 24-month progression-free survival rate was 79%, and the overall survival rate was 71.1%.</p><p><strong>Conclusion: </strong>The IMPATHI study demonstrates the potential of telemonitoring in the management of lung cancer patients receiving ICI therapy, with high compliance and promising survival outcomes. Telemonitoring offers significant benefits in early detection of adverse events and personalized care to patients. Future efforts should focus on expanding access to telemonitoring for all patients.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"149-156"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Vaccination of children and adolescents treated for acute leukemia, excluding HSCT recipients: Recommendations of the French Society for Childhood and Adolescent Cancer and Leukemia (SFCE)].","authors":"Aphaia Roussel, Camille Léglise, Fanny Rialland, Mylène Duplan, Fanny Falaque, Cécile Boulanger, Aude Marie Cardine, Aurélia Alimi, Cécile Pochon, Florence Rabian, Cléo Hautefeuille, Alizée Corbel, Chrystelle Dupraz, Cyril Lervat, Fanny Alby-Laurent","doi":"10.1016/j.bulcan.2024.10.013","DOIUrl":"10.1016/j.bulcan.2024.10.013","url":null,"abstract":"<p><p>Children and adolescents who are being treated or have been treated for acute leukemia have a secondary immunodeficiency linked to chemotherapy, resulting in an increased risk of infections. Some of which can be prevented by vaccination but its effectiveness is not optimal during chemotherapy. Upon cessation of chemotherapy, the time required for immune reconstitution varies from three months to more than a year, depending on lymphocyte subpopulations, the patient's age, and the intensity of the treatment received. Although they may have regained their immune functions, studies show that most patients have lost part of their vaccine-induced protection post-chemotherapy and require booster doses of vaccines. Most practitioners agree on the importance of vaccinating or revaccinating these children, but practices are heterogeneous among pediatric hematologist-oncologists in France. Based on a practice study and a recent review of the literature, this work aims to propose new French recommendations for the vaccination strategy to be adopted for children and adolescents treated or recently treated for acute leukemia, excluding allogeneic transplant recipients, in 2024. These recommendations specifically include the vaccination protocols for human papillomavirus and meningococcal infections but do not address the COVID-19 vaccination, as its guidelines are subject to rapid changes.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"208-224"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Cancer and nutritional management of overweight and obesity: Practice evaluation].","authors":"Léo Pernaton, Dominique Cellier, Romain Buono, Antoine Pierre, Marine Sauzet, Jean-Yves Blay, Olivia Pérol, Béatrice Fervers","doi":"10.1016/j.bulcan.2024.10.011","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.10.011","url":null,"abstract":"<p><strong>Context: </strong>The aim of this practice evaluation was to assess weight trends during and after a nutritional intervention in cancer patients and survivors.</p><p><strong>Methods: </strong>This retrospective study was conducted between January 2014 and October 2020 in adults with different cancer types managed at the Léon-Bérard Cancer Center, undergoing treatment or during post-treatment follow-up, with a BMI≥25kg/m² and who had at least 3 consultations with a nutrition physician. Nutritional management focused on behavioral, metabolic and nutritional aspects. Anthropometrics measurements, i.e., waist circumference, weight and BMI, were monitored prospectively during the nutritional consultation. The aim of this study was to evaluate the impact of the nutritional intervention on the anthropometrics measurements.</p><p><strong>Results: </strong>Overall, 247 patients were included in the analysis. The median duration of the nutritional intervention was 7.2months. Between the first and the last nutrition consultation, waist circumference was reduced in 97.2% of the patients, with a median loss of 10cm; weight and BMI were reduced in 85.0% and 83.8% of the patients respectively. Six months after the end of the nutritional intervention, 53.7% of patients had stable or continued reduced weight.</p><p><strong>Conclusion: </strong>This analysis of practice shows the positive impact of a nutritional intervention during cancer treatments on anthropometric parameters, and maintenance or continued weight loss at distance from the intervention in half of the patients.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone sarcomas and cancer predisposition syndromes.","authors":"Camille Tlemsani, Gaëlle Bougeard, Marion Gauthier-Villars, Philippe Denizeau, Sarah Winter, Caroline Michot, Geneviève Baujat, Brigitte Bressac, Tiphaine Adam de Beaumais, Aymeric Rouchaud, Fadila Mihoubi-Bouvier, Franck Bourdeaut, Laurence Brugières, Thierry Leblanc, Edwige Kasper, Nadège Corradini","doi":"10.1016/j.bulcan.2024.10.014","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.10.014","url":null,"abstract":"<p><p>Bone sarcomas, constituting less than 1% of malignant neoplasms across all age groups, are rare tumours possibly associated with genetic susceptibility syndromes. This review aims to provide recommendations for the detection of cancer predisposition syndromes associated with bone sarcomas and managing affected patients. Recommendations were formulated by a multidisciplinary working and reviewing group from GROUPOS and SFCE oncogenetic's group, including geneticists, oncologists, and radiologists. For various bone sarcomas including osteosarcomas, chondrosarcomas and Ewing sarcomas, we delineate tumour presentation, management strategies, and follow-up within the context of cancer predisposition syndromes. The inherited predisposition syndrome, associated with germline TP53 variants, known as the Li-Fraumeni syndrome, is the most frequent implicated in osteosarcoma cases. Other cancer predisposition syndromes, such as RB1, RECQ or CDKN2A disorders in osteosarcomas and Ollier and Maffucci diseases in chondrosarcomas, are also recognized. Additionally, we discuss rarer cancer predisposition syndromes associated with bone sarcomas and suggest tailored treatment approaches in some cancer predisposition syndromes to mitigate severe toxicities or secondary oncological events. Furthermore, we emphasize the role of identification somatic molecular variations in identifying constitutional germline variants and describe national and international screening programs, reference networks and molecular tumour boards available for collegial and collaborative management discussion. This comprehensive review provides insights into the intricate interplay between genetic predisposition, tumour biology, and therapeutic interventions in bone sarcoma patients with cancer predisposition syndrome.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient views on continued immune checkpoint inhibition following progression in advanced melanoma: A qualitative study.","authors":"Chloé Prod'homme, Nicolas Sena, Emmanuelle Forestier, Rozenn Le Berre, Eve Desmedt, Laurent Mortier, Licia Touzet","doi":"10.1016/j.bulcan.2024.12.011","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.12.011","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibition has revolutionized the management of metastatic melanoma, including in the final stages of disease progression: because it is well tolerated, some teams do not discontinue it in hopes of slowing disease progression. The risks are that treatment may be continued unnecessarily, causing side effects, and reduce access to specialist palliative care, in addition to increasing the cost of treatment.</p><p><strong>Method: </strong>We explored the experiences of 10 patients in a university hospital with metastatic melanoma under continued immune checkpoint inhibitors combined with specialist palliative care. Our goal was to gain a better understanding of the advantages and disadvantages perceived by patients. The comprehensive interviews were analysed using a method inspired by grounded theory that met the COREQ international recommendation criteria.</p><p><strong>Results: </strong>Receiving the information of disease progression, continued treatment and onset of palliative care impacts patients' lives: from this point onwards, death becomes a reality and takes on the image of a sword of Damocles. The experience is anxiety-provoking because of the uncertainty of tomorrow, and painful because of the physical suffering and successive bereavements. However, far from causing depression and despair, joint oncology-palliative management is well accepted and helps to improve patients' daily lives and well-being.</p><p><strong>Conclusion: </strong>Our findings highlight patients' ambivalence. On the one hand, they recount their experiences of suffering in connection with the disease and the confrontation with death, and on the other hand, their need to continue to live and to hope. Joint care provided by oncology and palliative care teams, symbolically representing hope and death, may mirror patients' psychological mindset and provide just the support they need.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Diet guidelines in adult and pediatric patient after allogeneic stem cell transplantation (SFGM-TC)].","authors":"Carole Farrugia, Alexandra Lhostette, Marion Brasseur, Thomas Biot, Hélène Calmes, Caroline Dendoncker, Anne Sophie Dupret, Sophie Estheve, Sylivie Filiol, Virginie Guidi, Lisa Hadrot, Manon Perez, Aurélie Ravinet, Laure Tardieu, Léonardo Magro, Serge Alfandari, Nicolas Simon, Sarah Guenounou, Jérôme Cornillon","doi":"10.1016/j.bulcan.2024.04.014","DOIUrl":"10.1016/j.bulcan.2024.04.014","url":null,"abstract":"<p><p>The nutritional status after bone marrow transplant plays an important role in the outcome of patients. Post-allograft dietary instructions are therefore essential to ensure quality nutrition while minimizing the risk of infection. For patients, this is one of their main concerns on discharge from hospital. With the aim of harmonizing post-allograft dietary instructions, a multidisciplinary working group has been set up within a number of French centers performing hematopoietic stem cell allogenic transplantation. The dietary guidelines have been updated by this working group, through videoconference meetings, an online questionnaire, a review of the literature and deliberations at harmonization days. These instructions will be incorporated into the next update of the adult and pediatric post-transplant follow-up booklet.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S87-S91"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Update for cord blood unit selection in hematopoietic stem cell transplantation (workshop SFGM-TC)].","authors":"Valérie Dubois, Lucie Blandin, Marion Duclaut, Alix Duquesne, Lionel Faivre, Romain Ferru-Clement, Jean Roy, Alexandre Walencik, Leonardo Magro, Federico Garnier","doi":"10.1016/j.bulcan.2024.01.009","DOIUrl":"10.1016/j.bulcan.2024.01.009","url":null,"abstract":"<p><p>Changing practices and the limited use of cord blood units as a source of cells for allogeneic hematopoietic stem cell transplants (HSC) led us to reconsider the recommendations established in 2011 and 2012, and to propose an update incorporating recent bibliographic data. If HLA compatibility was until now established at low resolution for HLA-A and B loci, and at high resolution for HLA-DRB1, the recent papers are converging towards an increase in the level of resolution, making way for a compatibility now defined in high resolution for all the considered loci, and the inclusion of the HLA-C locus, in order to establish a level of HLA compatibility on 8 alleles (HLA-A, B, C and DRB1). The CD34+ dose is a determining factor in hematopoietic reconstitution but it is not correlated with the total nucleated cells content. This is why we recommend taking these two data into account when choosing a cord blood unit. The recommendations established by our group are presented as a flow chart taking into account the characteristics of the underlying pathology (malignant or non-malignant), the cell dose and the HLA compatibility criteria, as well as criteria linked to the banks in which units are stored.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S68-S77"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Survival after cancer on Reunion Island].","authors":"Mohamed Khettab, Franck Ah-Pine, Emeline Colomba, Phuong Lien Tran, Jean-François Delattre, Luc Bauchet, Emmanuel Chirpaz","doi":"10.1016/j.bulcan.2024.12.003","DOIUrl":"10.1016/j.bulcan.2024.12.003","url":null,"abstract":"","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"111-112"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}